Nzs Capital, LLC Catalent, Inc. Transaction History

Nzs Capital, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$45.44 - $74.26 $2.63 Million - $4.3 Million	57,870 Added 74.95%	135,085 $8.88 Million
Q3 2022 Nov 14, 2022	SELL	$72.36 - $113.1 $1.88 Million - $2.93 Million	-25,929 Reduced 25.14%	77,215 $5.59 Million
Q2 2022 Aug 15, 2022	BUY	$87.2 - $114.05 $4.99 Million - $6.52 Million	57,173 Added 124.37%	103,144 $11.1 Million
Q1 2022 May 16, 2022	BUY	$94.19 - $124.49 $1.25 Million - $1.65 Million	13,293 Added 40.68%	45,971 $5.1 Million
Q4 2021 Feb 14, 2022	BUY	$119.57 - $139.07 $326,784 - $380,078	2,733 Added 9.13%	32,678 $4.18 Million
Q3 2021 Nov 12, 2021	BUY	$109.17 - $142.35 $879,255 - $1.15 Million	8,054 Added 36.79%	29,945 $3.99 Million
Q2 2021 Jul 22, 2021	BUY	$100.34 - $115.69 $2.2 Million - $2.53 Million	21,891 New	21,891 $2.37 Million

514

149M

575K

2.03M

Ticker CTLT
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 179,896,000
Market Cap $10.9B
Description
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products,...

Get notified when there are updates to the investment portfolio of Nzs Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Nzs Capital, LLC with notifications on news.